Please assess the completion status of the following clinical trial:

Trial Title: A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 9 to 18 months on the day of inclusion~* In good general health, without significant medical history~* Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations~* Subject and parent/legally acceptable representatives able to attend all scheduled visits and comply with all trial procedures~* Completion of vaccinations according to the national immunization schedule.~Exclusion Criteria :~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing any of the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator~* Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of the immune response~* Previous vaccination against flavivirus disease, including Japanese encephalitis (JE)~* Administration of any anti-viral within 2 months preceding first vaccination and up to the 4 weeks following the last trial vaccination at Month 3~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination~* Planned receipt of any vaccine from the inclusion up to the 4 weeks following the last trial vaccination~* Planned receipt of any Japanese encephalitis vaccine during the course of the study~* History of central nervous system disorder or disease, including seizures~* History of flavivirus infection (confirmed either clinically, serologically or microbiologically)~* Febrile illness (temperature ≥ 38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- JE-CV Group (Type: EXPERIMENTAL): Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
- SA14-14-2 vaccine Group (Type: ACTIVE_COMPARATOR): Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete